Compositions and methods for treating cancer with Anti-ror1 immunotherapy
An antigen and antibody technology, applied in the field of cancer, can solve problems such as patient failure
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0291] Isolation of ROR1-specific binders from fully human phage and yeast (Yeast)-displayed scFv libraries
[0292] Materials and methods
[0293] a) Generation of fully human ScFc (ScFv with Fc domain for analysis) binders to human ROR1
[0294] An initial human scFv (recombinant single-chain variable fragment of immunoglobulin) phage display library (approximate diversity, 10) constructed from peripheral blood B cells of 50 healthy donors 10 Unique specificity) (Z.Y. Zhu and D.S. Dimitrov, unpublished data) was used to select scFv of recombinant human ROR1 protein. will be 10 12 Amplified libraries of phage-displayed scFv were incubated with 5, 3, and 1 μg of coated ROR1 in 5 × 100-μl volumes, homogenized at room temperature during the first, second, and third rounds of biopanning, respectively. Distribute in 5 wells of a 96-well plate for 2 hours. After each round of incubation, the wells were washed with phosphate-buffered saline (PBST) containing 0.05% Tween 20 (5 wa...
Embodiment 2
[0302] CAR expressing anti-ROR1 fully human binding sequence.
[0303] Homo sapiens ROR1 (receptor tyrosine kinase-like orphan receptor 1) is a well-studied carcinoembryonic cell surface glycoprotein that is involved in chronic lymphocytic leukemia (CLL) and various solid tumors such as lung adenocarcinoma Carcinoma, sarcoma, or a subset of carcinomas). A phase I study of the anti-ROR1 antibody UC-961 (cetuzumab) in relapsed or refractory chronic lymphocytic leukemia is currently underway (sponsor, Thomas Kipps, NCT02222688). The results of this first-of-its-kind study are pending. Also in early stages is a phase 1 clinical trial with a CAR-T specific for ROR1 (sponsor, Fred Hutchinson Cancer Research Center, NCT02706392). We have included published ROR1 binders as our controls (LTG1943, LTG2527) (see Hudecek et al., 2013, Clin Cancer Res 19:3153-3164) to benchmark our studies and show the efficacy of our constructs. active. Given recent advances in T cell-based therapy, i...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com